To Compare Treatment With Doxorubicin or Capecitabine for Metastatic Breast Cancer in Women 60 Years and Older
Status:
Terminated
Trial end date:
2005-12-01
Target enrollment:
Participant gender:
Summary
The main purpose of this study is to compare treatment with either pegylated liposomal
doxorubicin or capecitabine as first line chemotherapy for metastatic breast cancer in women
60 years and older.
Phase:
Phase 3
Details
Lead Sponsor:
Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
Collaborator:
Tibotec Therapeutics, a Division of Ortho Biotech Products, L.P., USA